Alterations in lipid metabolism are present in both STZ-T1DM and T2DM, but therapeutic targets on lipid metabolism, such as PPAR agonists or CD36 antagonists, to prevent diabetes-induced TIF should be adapted to the diabetes type. The gene discussed is CD36; the disease is type 2 diabetes mellitus.